
Astellas, Evopoint Ink Exclusive Deal for CLDN18.2-Targeting ADC XNW27011
Astellas Secures Global Rights to Evopoint’s Promising CLDN18.2-Targeting Antibody-Drug Conjugate XNW27011 in Strategic Oncology Expansion In a strategic move that reinforces its commitment to precision oncology, Astellas Pharma Inc. has…













